The agreement covers PNT2002, a PSMA-directed radiopharmaceutical in phase 3 testing as a prostate cancer therapy, and neuroendocrine tumour (NET) therapy PNT2003, which targets a somatostatin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback